THE WOODLANDS, Texas, April 29, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq:RPRX) announced it is collaborating with Feinberg School of Medicine and the Breast Cancer Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in the conduct of a physician sponsored IND investigating the potential for the use of Proellex® in the treatment of breast cancer in a window-of-opportunity design.
The study is being conducted by Seema Khan, MD, Bluhm Family Professor of Cancer Research at Northwestern University Feinberg School of Medicine and co-leader of the Breast Cancer Program. This will be a randomized, placebo-controlled, pre-surgical trial of oral Proellex at 12 mg daily vs. placebo. The study population will consist of 50 pre-and post-menopausal women with Stage I-III breast cancer found on diagnostic core needle biopsy. The duration of the treatment will be 2-10 weeks depending on the subject's surgical schedule. Assessments of markers of disease will be done both pre-and post-surgically and will include not only markers of hormonal status but markers of proliferation and apoptosis (programmed cell death) in the tumor.
Dr. Seema Kahn noted, "Northwestern is beginning to explore the effects of Proellex (Telapristone, CDB-4124), a new anti-progestin, in women with breast cancer in collaboration with Repros Therapeutics. Progesterone, like estrogen, has been implicated in the causation and progression of breast cancer, based on epidemiological and laboratory data. These data have led to the concept that anti-progesterone therapy could reverse the effects of endogenous female hormones, prompting us to test the potential of novel anti-progestins such as Proellex to treat breast cancer. Furthermore, many primary breast cancers are resistant to anti-estrogenic treatment, and others acquire resistance later in their course, adding to the rationale for the evaluation of this new anti-progesterone in breast cancer. Importantly, Proellex is already in clinical trials in women with benign gynecological conditions that are hormone-dependent, and safety data are reassuring." The trial is funded by the Breast Cancer Research Foundation, with additional support from Repros Therapeutics.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV